Ralph Ensley, MD
Advanced Heart Failure and Transplant Cardiology · Tulsa, OKNPI 1225082795
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,469 of the $11,142 with a category attached, or 76.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,426 and has fallen 54.2% since, to $1,571 in 2025.
Across 201 payments — averaging $55.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- ZOLL Respicardia, Inc.$2K
- Abiomed$2K
- Boston Scientific$918
- Heartflow, Inc.$702
- Acist Medical Systems, Inc.$645
- plus $3K from 24 others
Across 6 payments — averaging $3921.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$24K
What the payments were for
- Travel & lodging$2,67324%
- Food & beverage$8,46976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $2,486 |
| ZOLL Respicardia, Inc. | 2 | $1,950 |
| Abiomed | 28 | $1,928 |
| Boston Scientific | 40 | $918 |
| Heartflow, Inc. | 11 | $702 |
| Acist Medical Systems, Inc. | 3 | $645 |
| Cook Medical LLC | 6 | $518 |
| Impulse Dynamics (USA) Inc. | 3 | $317 |
| Edwards Lifesciences | 7 | $266 |
| Medtronic(2 entities) | 13 | $241 |
| Amgen | 11 | $183 |
| Novartis | 7 | $169 |
| Inari Medical, Inc. | 6 | $94 |
| Cvrx, Inc. | 3 | $81 |
| Pfizer | 3 | $81 |
| Cardiac Dimensions, Inc. | 3 | $72 |
| Daiichi Sankyo Inc. | 4 | $62 |
| Angiodynamics, Inc. | 3 | $59 |
| Sensible Medical Innovations Inc | 1 | $56 |
| Silk Road Medical, Inc. | 1 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Shockwave Medical, Inc | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,950
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,519
- OPTIMIZER$591
- Impella$536
- Cook Medical Peripheral Intervention$458
- RXI SYSTEMS$297
- FFRct$266
- Watchman$243
- CVI CONSUMABLES$226
- CARDIOMEMS$150
- HeartMate 3 Left Ventricular Assist Device$137
- CVI SYSTEMS$122
How this compares
Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 624 | $677,928 |
| JardianceEmpagliflozin | 299 | $339,778 |
| EntrestoSacubitril/Valsartan | 226 | $294,298 |
| XareltoRivaroxaban | 146 | $187,105 |
| Repatha SureclickEvolocumab | 83 | $74,741 |
| FarxigaDapagliflozin Propanediol | 38 | $37,289 |
| Ezetimibe | 440 | $23,514 |
| Praluent PenAlirocumab | 37 | $20,114 |
| Atorvastatin Calcium | 805 | $19,580 |
| Metoprolol Succinate | 570 | $14,965 |
| CorlanorIvabradine Hcl | 14 | $10,968 |
| ClopidogrelClopidogrel Bisulfate | 417 | $7,256 |
| Rosuvastatin Calcium | 219 | $6,596 |
| Potassium Chloride | 236 | $6,435 |
| Carvedilol | 526 | $5,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $677,928624 claims |
| Boehringer IngelheimJardiance | $39 | $339,778299 claims |
| NovartisEntresto | $169 | $294,298226 claims |
| AmgenCorlanor | $183 | $10,96814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Tulsa
- Steven StroudTulsa$39K
- Luis Meggo QuirozTulsa$19K
- John VannTulsa$9K
- Nina WilliamsTulsa$5K
- Luke CunninghamOklahoma City$70K
- Tarun DasariOklahoma City$2K
- Carol KepfordOklahoma City$716
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.